Verona Pharma to Present Phase 2b data with Ensifentrine in COPD at the European Respiratory Society International Congress 2020
LONDON and RALEIGH, N.C., Aug. 24, 2020 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will present new subgroup analysis from Phase 2b trials with nebulized ensifentrine in chronic obstructive pulmonary disease (“COPD”) at the European Respiratory Society (“ERS”) International Congress on Tuesday, September 8, 2020. The abstracts are available on the ERS website and will be published in a supplement of the September 2020 edition of the peer reviewed journal, European Respiratory Journal.
Tara Rheault, Vice President, R&D and Global Project Management at Verona Pharma, will present subgroup analysis of Phase 2b data, first reported by Verona Pharma on January 13, 2020, and March 26, 2018, demonstrating that nebulized ensifentrine as monotherapy or added on to tiotropium (Spiriva® Respimat®), a long acting anti-muscarinic (“LAMA”) bronchodilator, improves lung function in moderate to severe COPD patients regardless of smoking status or history of chronic bronchitis over 4 weeks.In addition to the oral presentation, Verona Pharma will highlight data demonstrating that nebulized ensifentrine added on to tiotropium over 4 weeks improved lung function, symptoms and quality of life in moderate to severe COPD patients who were either reversible (≥12% and 200 mL) to albuterol and non-reversible (<12% or 200 mL) at screening compared to placebo added on to tiotropium. Importantly, in non-reversible patients, a large, clinically meaningful and statistically significant improvement in QoL as measured by SGRQ‑C Total Score was observed.Details of Verona Pharma’s oral presentation and abstracts are listed below with links to the ERS website.Oral Presentation OA4787:
